A comparative analysis of drug safety withdrawals in the UK and the US (1971-1992): Implications for current regulatory thinking and policy

Social Science and Medicine

Volumn 61, Issue 5, 2005, Pages 881-892

  Abraham, John ^a   Davis, Courtney ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

Drug lag; Drug regulation; International comparison; Pharmaceutical industry; Review times; Safety withdrawals; UK; USA

Indexed keywords

ALFADOLONE; ALFAXALONE; AZARIBINE; BENOXAPROFEN; BROTIZOLAM; DILEVALOL; DOMPERIDONE; ENCAINIDE; FENCLOFENAC; FEPRAZONE; INDOMETACIN; INDOPROFEN; MEASLES MUMPS RUBELLA VACCINE; METIPRANOLOL; NOMIFENSINE; PERHEXILINE; SUPROFEN; TEMAFLOXACIN; TERODILINE; TIENILIC ACID; TRIAZOLAM; TRYPTOPHAN; ZIMELDINE; ZOMEPIRAC;

DRUG PRESCRIBING; INDUSTRIAL REGULATION; PHARMACEUTICAL INDUSTRY; SAFETY;

AMNESIA; ANAPHYLAXIS; BLOOD TOXICITY; CARCINOGENICITY; CARDIOTOXICITY; COMPARATIVE ANATOMY; DRUG APPROVAL; DRUG INDUSTRY; DRUG SAFETY; DRUG WITHDRAWAL; EUROPE; GASTROINTESTINAL TOXICITY; GOVERNMENT; GRANULOMATOSIS; HEALTH CARE POLICY; HEART ARRHYTHMIA; HEMOLYTIC ANEMIA; HEMOLYTIC UREMIC SYNDROME; HUMAN; INTERVIEW; LIVER INJURY; LIVER TOXICITY; MENTAL DISEASE; MORTALITY; NEPHROTOXICITY; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; POSTMARKETING SURVEILLANCE; RESEARCH; REVIEW; SIDE EFFECT; SKIN TOXICITY; THROMBOEMBOLISM; TORSADE DES POINTES; UNITED KINGDOM; UNITED STATES; UVEITIS;

EASTERN HEMISPHERE; EURASIA; EUROPE; NORTH AMERICA; UNITED KINGDOM; UNITED STATES; WESTERN EUROPE; WESTERN HEMISPHERE; WORLD;

EID: 20444389780     PISSN: 02779536     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.socscimed.2005.01.004     Document Type: Article

References (51)

1. J. Abraham Bias in science and medical knowledge: The Opren controversy Sociology 28 1994 717 736
2. J. Abraham Science, politics and the pharmaceutical industry: Controversy and bias in drug regulation 1995 UCL/St. Martins Press London/New York
3. J. Abraham Transnational industrial power, the medical profession and the regulatory state: Adverse drug reactions and the crisis over Halcion in The Netherlands and the UK Social Science & Medicine 55 2002 1671 1690
4. J. Abraham, and G. Lewis Regulating medicines in Europe: Competition, expertise and public health 2000 Routledge London
5. J. Abraham, and T. Reed Trading risks for markets: The international harmonization of pharmaceuticals Health, Risk & Society 3 2001 113 128
6. J. Abraham, and T. Reed Reshaping the carcinogenic risk assessment of medicines: International harmonization for drug safety, industry/regulator efficiency or both? Social Science & Medicine 57 2003 195 204
7. J. Abraham, and J. Sheppard The therapeutic nightmare: The battle over the world's most controversial sleeping pill 1999 Earthscan London
8. F. Andersson The drug lag issue: The debate seen from an international perspective International Journal of Health Services 22 1992 53 72
9. Anon Zelmid Swedish ADR report Scrip 798 1983 18
10. Anon Hoechst withdraws nomifensine Scrip 1072 1986 22
11. Anon Editorial lessons from nomifensine Lancet II 1988 1059 1060
12. Anon Terodiline withdrawn worldwide Scrip 1653 1991 19
13. Anon Temafloxacin - anatomy of a withdrawal Scrip 1737 1992 20
14. A. Ault McClellan's FDA: Boon to industry, consumers, or both? New FDA chief plans to speed drug approval and reduce costs Lancet 362 2003 379 380
15. O.M. Bakke, M. Manocchia, F. de Abajo, K.I. Kaitin, and L. Lasagna Drug safety discontinuations in the UK, US, and Spain from 1974 through 1993: A regulatory perspective Clinical Pharmacology & Therapetics 58 1995 108 117
16. O.M. Bakke, W.M. Wardell, and L. Lasagna Drug discontinuations in the UK and the US, 1964 to 1983: Issues of safety Clinical Pharmacology & Therapeutics 35 1984 559 567
17. Barker, E. F. (1984). Endyne, internal FDA memorandum regarding new drug application for indoprofen, 25 May (END 0154).
18. Botstein, P. (1991). FDA non-approvable letter by deputy director of Office of Drug Evaluation, 29 July.
19. Carreras, J. A. (1991). Medical officer's review of NDA 20-196 (metipranolol 0.1%), 12 October, FDA (OPT 0015).
20. CAST Investigators Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction New England Journal of Medicine 321 1989 406 412
21. Chambers, W. A. (1989). Medical officer's review of NDA 19-911 (metipranolol 0.6%), 21 February, FDA (MET 002).
22. CSM CSM update: Non-steroidal anti-inflammatory drugs and serious gastrointestinal adverse reactions - 2 British Medical Journal 292 1986 1190 1191
23. B. Davis, and D.R. Pearce An introduction to Althesin (CT 1341) Postgraduate Medical Journal June Supplement 1972 13 17
24. FDA. (1983). Minutes internal FDA meeting regarding zimeldine new drug application, 16 September.
25. FDA. (1992). Forty-second meeting of the Anti-Infective Drugs Advisory Committee, July 10, Rockville, Maryland.
26. FDA. (2002). FOIA release, MIC00275, 21 June.
27. Greene-Reed, T. (1991). FDA Medical Officer's review of temafloxacin, 28 August.
28. House of Commons. (1984). Parliamentary Debates, Hansard, 61, 12 June, w.col. pp. 461-462.
29. W. Inman Don't tell the patient: Behind the drug safety net 1999 Highland Park Productions Bishops Waltham, Hampshire/ Los Angeles
30. D.B. Jefferys, D. Leakey, J.A. Lewis, S. Payne, and M.D. Rawlins New active substances authorised in the United Kingdom between 1972 and 1994 British Journal of Clinical Pharmacology 45 1998 151 156
31. K.I. Kaitin, and E.M. Healy The new drug approvals of 1996, 1997 and 1998: Drug development trends in the user fee era Drug Information Journal 34 2000 1 14
32. K.I. Kaitin, N. Mattison, F.K. Northington, and L. Lasagna The drug lag: An update of new drug introductions in the US and in the UK, 1977 through 1987 Clinical Pharmacology and Therapeutics 46 1989 121 138
33. D.A. Kessler, A.E. Hass, K.L. Felden, M. Lumpkin, and R. Temple Approval of new drugs in the US: Comparison with the UK, Germany and Japan Journal of the American Medical Association 276 1996 1826 1831
34. D. LaPlane, and M.G. Bousser Polyneuropathy during perhexiline maleate Therapy International Journal of Neurology 15 1981 293 300
35. J. Lexchin The timeliness of new drug approvals in Canada: A rejoinder International Journal of Health Services 25 1995 167 171
36. R.D. Mann Lessons from nomifensine Lancet II 1988 1490 1491
37. M.K. Olson Agency rulemaking, political influences, regulation and industry compliance Journal of Law, Economics and Organization 15 1999 573 601
38. M.K. Olson Pharmaceutical policy change and the safety of new drugs Journal of Law and Economics XLV 2002 615 642
39. J. Parker Who has a drug lag? Managerial and Decision Economics 10 1989 299 309
40. A.S. Pieterse, R. Rowland, and D. Dunn Perhexiline maleate induced cirrhosis Pathology 15 1983 201 203
41. N.S.B. Rawson, and K.I. Kaitin Canadian and US drug approval times and safety considerations The Annals of Pharmacotherapy 37 2003 1403 1408
42. S.O. Schweitzer, M.E. Schweitzer, and M-J. Sourty-Le Guellec Is there a US drug lag? The timing of new pharmaceutical approvals in the G-7 countries and Switzerland Medical Care Research and Review 53 1996 162 178
43. Temple, R. (1990). Dilevalol. Internal FDA memorandum from the Director of Drug Evalation I, to C. Graham and R. Lipicky, April 11.
44. US Committee on Government Operations FDA's Regulation of the new drug Merital, Fifteenth Report by the Committee on Government Operations 1987 GPO Washington
45. US Congress. (1976). FDA's regulation of the drug "Triazure". Hearing before a Subcommittee of the Committee on Government Operations, 27 October. Washington DC: GPO.
46. US Congress. (1986). Oversight of the new drug review process and FDA's regulation of Merital. Hearing before a Sub-Committee of the Committee on Government Operations, 22 May, Washington DC: GPO.
47. US District Court. (1984). United States of America v. SmithKline et al. Change of Plea Hearing before the Honorable Edward N Cahn, Eastern District of Pennsylvania, Docket No: CR 84-227, 12 December.
48. P.C. Waller, S.M. Wood, M.J.S. Langman, A.M. Breckenridge, and M.D. Rawlins Review of company postmarketing surveillance studies British Medical Journal 304 1992 1470 1472
49. W. Wardell Introduction of new therapeutic drugs in the US and Great Britain: An international comparison Clinical Pharmacology and Therapeutics 14 1973 773 790
50. M.E. Wiktorowicz Emergent patterns in the regulation of pharmaceuticals: Institutions and interests in the US, Canada, Britain and France Journal of Health Politics, Policy and Law 28 2003 615 658
51. R.N. Wild Micturin and torsades de pointes - experience of a post-marketing alert Pharmacoepidemiology and Drug Safety 1 1992 147 150